



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

On 18 Oct. 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Malinda Wojcik

*#4a* *1/26/02* *Tracy*  
PATENT  
Attorney Docket No.: 018623-015720US  
Client Ref. No.: EPI 0157.20US

**RECEIVED**  
JAN 14 2002  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

FIKES *et al.*

Application No.: 09/583,200

Filed: May 30, 2000

For: HLA CLASS I A2 TUMOR  
ASSOCIATED ANTIGEN PEPTIDES  
AND VACCINE COMPOSITIONS

Examiner: Schwadron, Ronald B.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Examiner's Communication mailed September 21, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.